Literature DB >> 12755355

Management of labour among women with epidural analgesia.

Christine L Roberts1, Camille H Raynes-Greenow, Alexis Upton, Ian D Douglas, Brian Peat.   

Abstract

To assess current practices in the labour management of low risk primiparous women with epidural analgesia we surveyed delivery suites in New South Wales (NSW) that annually provide at least 100 epidurals to 'standard primipara'. Epidural rates among 'standard primipara' at these hospitals ranged from 14 to 85% (median 46%). Continuous epidural infusion was the most commonly used technique (63%). For 'standard primipara' with an epidural 62% of units usually augmented labour with oxytocin, 89% discontinued the epidural in second stage and 67% had policies of delayed pushing. There is wide variation in epidural availability and in labour management, perhaps reflecting the limited evidence for effective interventions to reduce any unintended effects of epidural analgesia.

Entities:  

Mesh:

Year:  2003        PMID: 12755355     DOI: 10.1046/j.0004-8666.2003.00018.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  3 in total

1.  Maternal Body Mass Index and Regional Anaesthesia Use at Term: Prevalence and Complications.

Authors:  Frances M Biel; Nicole E Marshall; Jonathan M Snowden
Journal:  Paediatr Perinat Epidemiol       Date:  2017-08-22       Impact factor: 3.980

2.  Continuing epidural analgesia during the second stage and ACOG definition of arrest of labor on maternal-fetal outcomes.

Authors:  ShengXing Zheng; Wenwen Zheng; Tianqi Zhu; Haiyan Lan; Qian Wang; Xiao Sun; MingPin Hu
Journal:  Acta Anaesthesiol Scand       Date:  2020-05-14       Impact factor: 2.105

Review 3.  Discontinuation of epidural analgesia late in labour for reducing the adverse delivery outcomes associated with epidural analgesia.

Authors:  S Torvaldsen; C L Roberts; J C Bell; C H Raynes-Greenow
Journal:  Cochrane Database Syst Rev       Date:  2004-10-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.